Arrowhead's First Commercial Year Is Here, but Revenue May Not Show It

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Arrowhead typically reports earnings after the market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Arrowhead's post-earnings price action has been highly volatile, with an average absolute Day 0 move of 4.85% and an average Day +1 move of 9.29%—both well above typical biotech volatility. The Day +1 range averages 12.81%, indicating significant intraday swings as investors digest results and management commentary.

The most dramatic moves came in November 2025, when the stock surged +23.34% on Day +1 following fiscal year 2025 results, likely driven by the REDEMPLO approval and strong partnership revenue. The February 2026 report saw a -5.02% Day 0 decline, followed by relative stability on Day +1. More recently, the August 2026 report (fiscal Q3 2026) showed a +4.16% Day 0 gain, but then reversed -2.99% on Day +1, suggesting initial optimism gave way to concerns about the widening loss despite the revenue beat.

The pattern suggests investors should expect significant volatility around this release, with the direction heavily dependent on management's commentary around REDEMPLO uptake, the SHTG filing timeline, and operating expense guidance. The wide Day +1 ranges indicate that conference call tone and forward guidance often matter more than the headline numbers themselves.

Part 2.2: Options Market Expected Move

The options market is pricing an 8.79% expected move for the November 20 expiration, slightly below the 9.29% average Day +1 move observed in recent earnings reports. This suggests options traders are anticipating meaningful volatility, but not quite at the extreme levels seen in some prior quarters (such as the 23.34% Day +1 surge in November 2025). The expected move range of $44.79 to $53.43 brackets the current price, indicating the market sees roughly balanced risk to the upside and downside.

Part 3: What Analysts Are Saying

Analyst sentiment on Arrowhead is decidedly bullish, with a consensus rating of 4.80 out of 5.0 (between Buy and Strong Buy). The breakdown shows 13 Strong Buys, 1 Moderate Buy, and 1 Hold, with no sell ratings. This represents an improved sentiment trend from one month ago, when the consensus stood at 4.79 with 12 Strong Buys.

The average price target of $107.71 implies 118% upside from the current price of $49.34, with a range from a low of $74.00 to a high of $126.00. The wide target range reflects differing views on execution risk and the value of Arrowhead's pipeline. The high-end targets from firms like Piper Sandler ($126) and Morgan Stanley ($120) are anchored on the assumption that plozasiran achieves blockbuster status in SHTG and that the broader pipeline delivers multiple commercial products. The more conservative targets, including Goldman Sachs' $74, reflect caution around near-term profitability and the competitive landscape in RNAi therapeutics.

The recent shift toward more bullish ratings and higher price targets reflects growing confidence following the positive SHASTA trial results and successful ARO-MAPT and ARO-DIMER-PA readouts. Analysts have cited "updated assumptions on fair value" and "growing optimism around upcoming SHASTA-3/4 data" as drivers of the improved outlook. However, the presence of a Neutral rating from a major firm like Goldman Sachs underscores that not all analysts are convinced the current valuation fully accounts for execution risk, particularly around the commercial ramp of REDEMPLO and the timeline for SHTG approval.

Part 4: Technical Picture

Arrowhead's technical setup heading into earnings is decidedly weak. The Barchart Technical Opinion currently stands at 88% Sell, up from 72% Sell one week ago and 56% Sell one month ago—a Strong signal that is Strengthening. The stock is trading at $49.34, below all key moving averages: the 5-day ($52.64), 10-day ($56.43), 20-day ($57.42), 50-day ($64.86), 100-day ($74.24), and 200-day ($71.28). This across-the-board weakness indicates sustained selling pressure and deteriorating momentum across all timeframes.

Timeframe Analysis:

• Short-term (100% Sell): The unanimous sell signal reflects severe near-term weakness, with the stock breaking below short-term support levels and showing no signs of stabilization
• Medium-term (100% Sell): The intermediate trend is equally bearish, suggesting the recent decline is more than just a short-term pullback and reflects a broader shift in sentiment
• Long-term (50% Sell): The moderate sell signal in the longer-term timeframe indicates the stock has given back a significant portion of its prior gains, though the long-term trend is less decisively negative than shorter timeframes

Trend Characteristics: The Strong and Strengthening trend indicates accelerating downside momentum, with selling pressure intensifying rather than abating—a cautionary signal heading into a potentially volatile earnings event.

The stock has declined sharply from its 52-week high of $95.49 to the current level of $49.34, a drawdown of nearly 50%. The breakdown below the 200-day moving average at $71.28 is particularly concerning from a technical perspective, as it suggests the long-term uptrend that carried the stock higher through much of 2025 and early 2026 has been broken. The fact that the stock is trading below even the short-term 5-day moving average indicates no near-term support has been established.

Heading into earnings, the technical setup is decidedly unfavorable. The combination of a Strong Sell signal, positioning below all moving averages, and accelerating downside momentum suggests the stock is vulnerable to further declines if results or guidance disappoint. However, the severity of the recent selloff also means the bar for a positive surprise may be lower, and any upside catalyst—such as better-than-expected REDEMPLO revenue or an accelerated SHTG filing timeline—could trigger a sharp reversal given the oversold conditions. Investors should be prepared for significant volatility in either direction.